155 related articles for article (PubMed ID: 24278004)
1. MicroRNA-gene association as a prognostic biomarker in cancer exposes disease mechanisms.
Ben-Hamo R; Efroni S
PLoS Comput Biol; 2013; 9(11):e1003351. PubMed ID: 24278004
[TBL] [Abstract][Full Text] [Related]
2. hsa-miR-9 controls the mobility behavior of glioblastoma cells via regulation of MAPK14 signaling elements.
Ben-Hamo R; Zilberberg A; Cohen H; Efroni S
Oncotarget; 2016 Apr; 7(17):23170-81. PubMed ID: 27036038
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA hsa-mir-3923 serves as a diagnostic and prognostic biomarker for gastric carcinoma.
Yang X; Zhang Z; Zhang L; Zhou L
Sci Rep; 2020 Mar; 10(1):4672. PubMed ID: 32170105
[TBL] [Abstract][Full Text] [Related]
4. Identification of prognostic biomarkers in glioblastoma using a long non-coding RNA-mediated, competitive endogenous RNA network.
Cao Y; Wang P; Ning S; Xiao W; Xiao B; Li X
Oncotarget; 2016 Jul; 7(27):41737-41747. PubMed ID: 27229531
[TBL] [Abstract][Full Text] [Related]
5. Gene expression and network-based analysis reveals a novel role for hsa-miR-9 and drug control over the p38 network in glioblastoma multiforme progression.
Ben-Hamo R; Efroni S
Genome Med; 2011 Nov; 3(11):77. PubMed ID: 22122801
[TBL] [Abstract][Full Text] [Related]
6. Primary tumor microRNA signature predicts recurrence and survival in patients with locally advanced esophageal adenocarcinoma.
Matsui D; Zaidi AH; Martin SA; Omstead AN; Kosovec JE; Huleihel L; Saldin LT; DiCarlo C; Silverman JF; Hoppo T; Finley GG; Badylak SF; Kelly RJ; Jobe BA
Oncotarget; 2016 Dec; 7(49):81281-81291. PubMed ID: 27793030
[TBL] [Abstract][Full Text] [Related]
7. A novel microRNAs expression signature for hepatocellular carcinoma diagnosis and prognosis.
Lu M; Kong X; Wang H; Huang G; Ye C; He Z
Oncotarget; 2017 Jan; 8(5):8775-8784. PubMed ID: 28060739
[TBL] [Abstract][Full Text] [Related]
8. Profiling of novel circulating microRNAs as a non-invasive biomarker in diagnosis and follow-up of high and low-grade gliomas.
Tabibkhooei A; Izadpanahi M; Arab A; Zare-Mirzaei A; Minaeian S; Rostami A; Mohsenian A
Clin Neurol Neurosurg; 2020 Mar; 190():105652. PubMed ID: 31896490
[TBL] [Abstract][Full Text] [Related]
9. A three-microRNA signature identifies two subtypes of glioblastoma patients with different clinical outcomes.
Marziali G; Buccarelli M; Giuliani A; Ilari R; Grande S; Palma A; D'Alessandris QG; Martini M; Biffoni M; Pallini R; Ricci-Vitiani L
Mol Oncol; 2017 Sep; 11(9):1115-1129. PubMed ID: 28248456
[TBL] [Abstract][Full Text] [Related]
10. Prognostic microRNA signatures derived from The Cancer Genome Atlas for head and neck squamous cell carcinomas.
Wong N; Khwaja SS; Baker CM; Gay HA; Thorstad WL; Daly MD; Lewis JS; Wang X
Cancer Med; 2016 Jul; 5(7):1619-28. PubMed ID: 27109697
[TBL] [Abstract][Full Text] [Related]
11. Biomarker microRNAs for prostate cancer metastasis: screened with a network vulnerability analysis model.
Lin Y; Chen F; Shen L; Tang X; Du C; Sun Z; Ding H; Chen J; Shen B
J Transl Med; 2018 May; 16(1):134. PubMed ID: 29784056
[TBL] [Abstract][Full Text] [Related]
12. A subgroup of microRNAs defines PTEN-deficient, triple-negative breast cancer patients with poorest prognosis and alterations in RB1, MYC, and Wnt signaling.
Wang DY; Gendoo DMA; Ben-David Y; Woodgett JR; Zacksenhaus E
Breast Cancer Res; 2019 Jan; 21(1):18. PubMed ID: 30704524
[TBL] [Abstract][Full Text] [Related]
13. Circulating microRNAs: potential biomarkers for common malignancies.
Khoury S; Tran N
Biomark Med; 2015; 9(2):131-51. PubMed ID: 25689901
[TBL] [Abstract][Full Text] [Related]
14. An integrative characterization of recurrent molecular aberrations in glioblastoma genomes.
Sintupisut N; Liu PL; Yeang CH
Nucleic Acids Res; 2013 Oct; 41(19):8803-21. PubMed ID: 23907387
[TBL] [Abstract][Full Text] [Related]
15. Serum miR-100 is a potential biomarker for detection and outcome prediction of glioblastoma patients.
Zhang H; Wang J; Wang Z; Ruan C; Wang L; Guo H
Cancer Biomark; 2019; 24(1):43-49. PubMed ID: 30530966
[TBL] [Abstract][Full Text] [Related]
16. Long non‑coding RNA FLVCR1‑AS1 promotes glioma cell proliferation and invasion by negatively regulating miR‑30b‑3p.
Gao W; Li H; Liu Y; Zhang Y; Zhao H; Liu F
Mol Med Rep; 2020 Aug; 22(2):723-732. PubMed ID: 32626942
[TBL] [Abstract][Full Text] [Related]
17. Low microRNA-139 expression associates with poor prognosis in patients with tumors: A meta-analysis.
Chen JA; Yu Y; Xue C; Chen XL; Cui GY; Li J; Li KF; Ren ZG; Sun RR
Hepatobiliary Pancreat Dis Int; 2019 Aug; 18(4):321-331. PubMed ID: 30290990
[TBL] [Abstract][Full Text] [Related]
18. The prognostic value of a seven-microRNA classifier as a novel biomarker for the prediction and detection of recurrence in glioma patients.
Chen W; Yu Q; Chen B; Lu X; Li Q
Oncotarget; 2016 Aug; 7(33):53392-53413. PubMed ID: 27438144
[TBL] [Abstract][Full Text] [Related]
19. Construction and validation of a three-microRNA signature as prognostic biomarker in patients with hepatocellular carcinoma.
Zhang X; Ma L; Zhai L; Chen D; Li Y; Shang Z; Zhang Z; Gao Y; Yang W; Li Y; Pan Y
Int J Med Sci; 2021; 18(4):984-999. PubMed ID: 33456356
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of serum microRNA-205 as a potential diagnostic and prognostic biomarker for human glioma.
Yue X; Lan F; Hu M; Pan Q; Wang Q; Wang J
J Neurosurg; 2016 Jan; 124(1):122-8. PubMed ID: 26230475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
